Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic Receives European CE Mark for Molecular Assay to Quantify Human Cytomegalovirus

Hologic Receives European CE Mark for Molecular Assay to Quantify Human Cytomegalovirus

Hologic (HOLX) management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenges faced in multiplexed point-of-care molecular testing.

Hologic (HOLX) to Beat Post-COVID Woes With Mobidiag Buyout

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #acquisition--Hologic Completes Acquisition of Mobidiag

Hologic Completes Acquisition of Mobidiag

Hologic's (HOLX) Acessa procedure new coverage will further validate Laparoscopic Radiofrequency Ablation as a standard of care for uterine fibroids.

Hologic (HOLX) Acessa Procedure Now Covered by Cigna Insurance

Costco

Zoom Video

These businesses are running out of steam. Now may be the time to hit the sell button on their stocks.

3 Growth Stocks That Could Be Headed for Trouble Once the Pandemic Ends

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Acessa--Cigna Updates Medical Policy to Cover Hologic's Acessa® Procedure, Expanding Access to Millions of Women Across the Country

Cigna Updates Medical Policy to Cover Hologic's Acessa® Procedure, Expanding Access to Millions of Women Across the Country

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Hologic (HOLX) Down 4.4% Since Last Earnings Report: Can It Rebound?

Hologic's (HOLX) ThinPrep Genesis processor offers new automation capabilities and workflow enhancements.

Hologic (HOLX) ThinPrep Genesis Processor Gets FDA Approval

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ACOG--New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation

New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Minimally Invasive, Uterine Preserving Treatment Option

Hologic is one of the top players in the fast-growing women's health and diagnostics businesses. Its stream of successes and its hyperfocused efforts on women's healthcare puts it on track to be the segment leader.

Hologic: One Of The Top Players In The Fast-Growing Women's Health And Diagnostics Businesses

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #breastcancer--Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer

Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer

Getting beyond COVID-19 starts with going back to the base business.

Will the End of the Pandemic Bring an End to This Healthcare Company?

Abbott Labs

Thermo Fisher Scientific

Investors should hold off permanently rebranding diagnostics stocks as coronavirus stocks, experts say. There's a chance their future could be much brighter despite spreading vaccine use.

Why Vaccines Might Not Spell Downturn For Covid Testing Firms

The stock price of Hologic (NASDAQ: HOLX), a medical devices company focused on women's health, has seen a large 12% drop in just five trading sessions. The decline was driven primarily due to the company's fiscal Q2 results, which came in slightly below the street estimates.

What's Next For Hologic Stock After The Recent 12% Drop?

Is (HOLX) Outperforming Other Medical Stocks This Year?

Is Hologic (HOLX) Stock Outpacing Its Medical Peers This Year?

Hologic (HOLX) exhibited robust segmental growth in second-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

Hologic (HOLX) Q2 Earnings Miss Estimates, Margins Rise

Hologic Inc (NASDAQ: HOLX) posted second-quarter results that trailed the consensus forecast; however, the company tried to provide some cushion with a better third-quarter fueled by COVID-19 test revenue. Q2 adjusted EPS of $2.59 missed the consensus of $2.61, while sales of $1.54 billion were roughly in-line.

Hologic Shares Drop On Q2 Earnings Miss; Q3 Guidance Trail Consensus

Hologic, Inc. (HOLX) CEO Stephen MacMillan on Q2 2021 Results - Earnings Call Transcript

Hologic (HOLX) delivered earnings and revenue surprises of -1.15% and -0.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Hologic (HOLX) Q2 Earnings and Revenues Miss Estimates

Shares of Hologic Inc. fell nearly 7% in the extended session Tuesday after the medical technology company missed Wall Street expectations for its adjusted profit in the fiscal second quarter and quarterly sales were in line with views. Hologic said it earned $619.9 million, or $2.38 a share, in the quarter, compared with $96 million, or 36 cents a share, in the year-ago period.

Hologic stock falls 7% after fiscal Q2 earnings miss

Shares of Hologic (NASDAQ:HOLX) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 354.39% year over year to $2.59, which missed the estimate of $2.61.

Recap: Hologic Q2 Earnings

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #earnings--Hologic Announces Financial Results for Second Quarter of Fiscal 2021

Hologic Announces Financial Results for Second Quarter of Fiscal 2021

Align Technology

Boston Scientific

Quest Diagnostics

Integra LifeSciences Holdings

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.

New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings

PerkinElmer

PRA Health Sciences

Here we discuss three MedTech subsectors, which encourage us with their consistency through the pandemic year and are likely to have continued with their winning streak in Q121.

News for Hologic Stock (HOLX)